Alnylam Pharmaceuticals (NasdaqGS:ALNY) experienced an 8% price increase over the past week, likely spurred by a positive opinion from the European Medicines Agency (EMA) regarding its RNAi ...

Alnylam Pharmaceuticals (NASDAQ:ALNY) and Halozyme Therapeutics (NASDAQ:HALO) announced Monday that an expert panel of the EU ...

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNA interference (RNAi) therapeutics company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European ...

UK MHRA grants marketing authorization to Bayer’s acoramidis to treat wild-type or variant transthyretin amyloidosis in adults with cardiomyopathy: United Kingdom Monday, April ...

The following is a summary of “Elevated serum concentrations of GFAP in hereditary transthyretin amyloidosis since pre-symptomatic stages,” published in the April 2025 issue of Journal of Neurology by ...

Announcing the passing of a loved one in local news media is a long standing tradition and we are proud of the trust placed ...

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved Beyonttra (acoramidis), from Germany’s Bayer ...

While Alnylam has not released an official statement regarding the financial impact of the CHMP’s recommendation, investors have responded favorably to the news. The stock’s upward movement reflects ...

The EMA’s Committee for Medicinal Products for Human Use adopted a positive opinion, recommending a change to the terms of the marketing ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has given the green light to acoramidis (Beyonttra) for adult ...

This year's game had an extra layer of emotion that brought the Panthers together. Assistant coach Hoa Nguyen is in a current ...

Alnylam and BridgeBio are competing for people who are switching from Pfizer’s blockbuster ATTR amyloidosis drug tafamidis ...